News
XRTX
1.850
+6.02%
0.105
XORTX Moves to File Health Canada Trial Application for XRx-026 Gout Program
TipRanks · 7h ago
Xortx Therapeutics outlines anticipated clinical trial application for XRx-026
TipRanks · 8h ago
Weekly Report: what happened at XRTX last week (0928-1002)?
Weekly Report · 3d ago
Weekly Report: what happened at XRTX last week (0921-0925)?
Weekly Report · 09/28 10:16
Weekly Report: what happened at XRTX last week (0914-0918)?
Weekly Report · 09/21 10:17
Biotech Stocks In Focus - IMCC +245%, XRTX +12%, SILO, BFRI
NASDAQ · 09/18 19:27
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 09/18 17:05
XORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A Year
NASDAQ · 09/18 12:35
Xortx Therapeutics announces planned FDA IND submission for XRx-026
TipRanks · 09/18 12:15
XORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program
Benzinga · 09/18 12:08
XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity
Barchart · 09/18 07:05
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/17 21:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 09/16 12:06
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 09/15 21:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 09/14 12:06
Weekly Report: what happened at XRTX last week (0907-0911)?
Weekly Report · 09/14 10:22
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Benzinga · 09/14 09:50
XORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know
Benzinga · 09/11 06:37
XORTX Begins Clinical, Commercial Manufacturing Of XORLO For Gout Program; Shares Surge To 31%
NASDAQ · 09/11 05:47
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 09/10 21:06
More
Webull provides a variety of real-time XRTX stock news. You can receive the latest news about Xortx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.